Celularity Inc.
NASDAQ:CELUBiotechnology
+$1.22 today
- Market cap
- $52.97M
- Beta
- 0.54
- P/E (TTM)
- -0.6
- EPS (TTM)
- -$3.58
Volume 0.00M
Average 0.13M
CELU Net Income
Bottom-line profit, the starting point for calculating cash from operations.
Celularity Inc.NASDAQ: CELU
Net Income · Q4 FY2025 · quarter ended Dec 2025
Net income growth accelerates
Q4 FY2025 net income of $24.36M (cash outflow) rose 83.3% year over year, ahead of the +58.4% change in trailing-twelve-month net income. Sequentially, it rose 5.6% from the prior quarter.
Context
- Net income amounted to 345.4% of revenue in FY2025, up 238.7 pp from a year earlier.
- Net income increased in 1 of the last 3 fiscal years.
What to watch
Whether net income reaches the consensus estimate from 1 analysts of -$70.4M (-23.2%) for the fiscal year ending Dec 2026, a slowdown from the +58.4% reported in FY2025.
Sources:Cash Flow Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterDec 2025
- -$24.36M+5.6% QoQ
- Last fiscal yearDec 2025
- -$91.72M+58.4% YoY
- LTMDec 2025
- -$91.72M+58.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +83.3% | — | — |
| 1 year | +58.4% | -23.2% | -81.7 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
Net Income history
USD · from the cash flow
- Latest · FY2025
- (91.72M) USD
- Year-over-year change
- -58.4%
| Period | Period end | Net Income | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (91.72M) | -58.4% |
| FY2024 | 2024-12-31 | (57.89M) | +70.5% |
| FY2023 | 2023-12-31 | (196.3M) | -1483.1% |
| FY2022 | 2022-12-31 | 14.19M | +114.2% |
| FY2021 | 2021-12-31 | (100.12M) | — |
Net Income vs competitors
How CELU compares with its peers on the latest reported figures
- CELU's LTM Dec 2025 net income of $91.72M is the largest of the 4 companies compared; the peer median is $34.17M.
- Its year-over-year change of +58.4% is the 2nd highest of 3, against a peer median of +84.2%.
- Net income amounts to 345.4% of revenue for CELU, versus a peer median of 32.2%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Dec 2025 | $91.72M | +58.4% | — | 345.4% | |
| LTM Mar 2026 | $40.92M | +40.8% | +944.4% | — | |
| LTM Dec 2025 | $34.17M | — | -4.8% | — | |
| LTM Jun 2026 | $11.31M | +127.6% | +0.9% | 32.2% | |
| Peer median (excluding CELU) | $34.17M | +84.2% | +0.9% | 32.2% | |
Competitors are the stored peer set for CELU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (100.12M) | 14.19M | (196.3M) | (57.89M) | (91.72M) |
| Depreciation & Amortization | 8.82M | 9.44M | 11.48M | 7.92M | 7.3M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 3K |
| Stock-Based Compensation | 40.01M | 15.86M | 15.02M | 11.57M | 10.38M |
| Change in Working Capital | (5.71M) | (15.45M) | (6.77M) | 22.2M | 33.59M |
| Accounts Receivables | (1.91M) | (3.58M) | (6.83M) | (3.97M) | 7.55M |
| Inventory | (6.42M) | (16.89M) | (865K) | 6.28M | 10.25M |
| Accounts Payables | 0 | 0 | 0 | 9.24M | 3.13M |
| Other Working Capital | 2.62M | 5.02M | 919K | 10.65M | 12.67M |
| Other Non-Cash Items | (53.1M) | (161.91M) | 137.89M | 9.8M | 27.19M |
| Operating Cash Flow | (110.1M) | (137.88M) | (38.69M) | (6.4M) | (13.25M) |
| Capital Expenditures | (6.2M) | (5.24M) | (4.05M) | (161K) | 0 |
| Acquisitions (Net) | 0 | 0 | 0 | (1.5M) | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 300K | 0 | 0 | 2.18M | 0 |
| Investing Cash Flow | (5.9M) | (5.24M) | (4.05M) | 514K | 0 |
| Debt Repayment | 0 | 39.2M | 11.31M | 7.1M | (121K) |
| Common Stock Issued | 638K | 53.37M | 5.43M | 58K | 24.42M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | (5.9M) |
| Other Financing Activities | 97.92M | 27.26M | 7.35M | (459K) | 255K |
| Financing Cash Flow | 98.56M | 119.84M | 24.09M | 6.7M | 18.65M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (17.44M) | (23.27M) | (18.64M) | 814K | 5.4M |
| Free Cash Flow | (116.3M) | (143.11M) | (42.73M) | (6.56M) | (13.25M) |
Celularity Inc.
NASDAQ:CELU
Intrinsic Alpha fair value
Locked
Current Price
$1.83
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.